Literature DB >> 6235619

Direct labelling of ipratropium bromide aerosol and its deposition pattern in normal subjects and patients with chronic bronchitis.

S G Spiro, C A Singh, S E Tolfree, M R Partridge, M D Short.   

Abstract

A technique for the direct labelling of ipratropium bromide with bromine-77, with reconstitution of the drug in a metered dose inhaler so as to be identical to the commercial product, was used to study drug deposition patterns in seven normal subjects and seven patients with chronic bronchitis (mean FEV1 32% (SD 12.2%) predicted normal). The gamma camera image of the thorax was divided into a middle zone--the mediastinal zone--and the lung itself into a central zone comprising its medial third and a peripheal zone, the lateral two thirds. Measurements after 10 inhalations of labelled ipratropium bromide showed similar results for the two groups of subjects. The total lung dose inhaled was 11.2% of 203 micrograms and 11.7% of 186 micrograms in the normal subjects and the patients respectively. In contrast to the deposition patterns seen in aerosol studies using steady state inhalation methods, there was no difference in deposition pattern--that is, the distribution between the central and the peripheral lung zones--between the normal subjects and the patients with airways obstruction.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6235619      PMCID: PMC459825          DOI: 10.1136/thx.39.6.432

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  7 in total

1.  Aerosol penetrance: a sensitive index of peripheral airways obstruction.

Authors:  M B Dolovich; J Sanchis; C Rossman; M T Newhouse
Journal:  J Appl Physiol       Date:  1976-03       Impact factor: 3.531

2.  Deposition of aerosols in pulmonary disease.

Authors:  I S Goldberg; R V Lourenço
Journal:  Arch Intern Med       Date:  1973-01

Review 3.  How should a pressurized beta-adrenergic bronchodilator be inhaled?

Authors:  S P Newman; D Pavia; S W Clarke
Journal:  Eur J Respir Dis       Date:  1981-02

4.  Pharmacokinetics of inhaled substances.

Authors:  D S Davies
Journal:  Postgrad Med J       Date:  1975       Impact factor: 2.401

5.  The labelling and monitoring of lung deposition of an inhaled synthetic anticholinergic bronchodilating agent.

Authors:  M D Short; C A Singh; J D Few; P R Studdy; P J Heaf; S G Spiro
Journal:  Chest       Date:  1981-12       Impact factor: 9.410

6.  Deposition of pressurized suspension aerosols inhaled through extension devices.

Authors:  S P Newman; F Morén; D Pavia; F Little; S W Clarke
Journal:  Am Rev Respir Dis       Date:  1981-09

7.  Deposition of pressurised aerosols in the human respiratory tract.

Authors:  S P Newman; D Pavia; F Morén; N F Sheahan; S W Clarke
Journal:  Thorax       Date:  1981-01       Impact factor: 9.139

  7 in total
  6 in total

1.  Comparison of bronchodilator responses and deposition patterns of salbutamol inhaled from a pressurised metered dose inhaler, as a dry powder, and as a nebulised solution.

Authors:  B M Zainudin; M Biddiscombe; S E Tolfree; M Short; S G Spiro
Journal:  Thorax       Date:  1990-06       Impact factor: 9.139

Review 2.  Studies using radiolabelled aerosols in children.

Authors:  M L Everard
Journal:  Thorax       Date:  1994-12       Impact factor: 9.139

Review 3.  Standards for bioequivalence of inhaled products.

Authors:  H Chrystyn
Journal:  Clin Pharmacokinet       Date:  1994-01       Impact factor: 6.447

4.  Pressurised aerosol deposition in the human lung with and without an "open" spacer device.

Authors:  S P Newman; A R Clark; N Talaee; S W Clarke
Journal:  Thorax       Date:  1989-09       Impact factor: 9.139

5.  Aerosol deposition in the human lung following administration from a microprocessor controlled pressurised metered dose inhaler.

Authors:  S J Farr; A M Rowe; R Rubsamen; G Taylor
Journal:  Thorax       Date:  1995-06       Impact factor: 9.139

6.  Customized 3D-printed stackable cell culture inserts tailored with bioactive membranes.

Authors:  Asli Aybike Dogan; Martin Dufva
Journal:  Sci Rep       Date:  2022-03-07       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.